63285-59-6

Basic information

• Product Name: ETHYL 1-BENZYL-4-METHYLPIPERAZINE-2-CARBOXYLATE
• Synonyms: ETHYL 1-BENZYL-4-METHYLPIPERAZINE-2-CARBOXYLATE
• CAS NO: 63285-59-6
• Molecular Formula: C₁₅H₂₂N₂O₂
• Molecular Weight: 262.34738
• Mol File: 63285-59-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 1-BENZYL-4-METHYLPIPERAZINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 1-BENZYL-4-METHYLPIPERAZINE-2-CARBOXYLATE(63285-59-6)
• EPA Substance Registry System: ETHYL 1-BENZYL-4-METHYLPIPERAZINE-2-CARBOXYLATE(63285-59-6)

Safety Data

• Hazardous Substances Data: 63285-59-6(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 134749-45-4 ethyl 1-benzylpiperazine-2-carboxylate 
• 56904-09-7 N-methyl-2-(benzylamino)ethylamine 
• 3674-13-3 2,3-dibromopropionic acid ethyl ester 
• 129798-91-0 ethyl piperazine-2-carboxylate dihydrochloride 
• 162510-56-7 1-tritylpiperazin-3yl-carboxylic acid ethyl ester 
• 604785-27-5 1-Benzyl-4-trityl-piperazine-2-carboxylic acid ethyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 63285-60-9 4-Methyl-2-piperazincarbonsaeure-aethylester 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT

The invention relates to CGRP antagonists of general formula (I), in which A, U, V, W, X and R1 to R 3 are as defined in claim 1, the tautomers, diastereomers, enantiomers, hydrates, mixtures, salts, hydrates of the salts, in particular the physiologically-acceptable salts thereof with inorganic or organic acids, medicaments containing said compounds and the use and methods for production thereof.

Hybridized and isosteric analogues of N1-acetyl-N4-dimethyl-piperazinium iodide (ADMP) and N1-phenyl-N4-dimethyl-piperazinium iodide (DMPP) with central nicotinic action

A series of piperazine derivatives, obtained by hybridization of N1-acetyl-N4-dimethyl-piperazinium iodide (1, ADMP) and N1-phenyl-N4-dimethyl-piperazinium iodide (3, DMPP) or of the corresponding tertiary bases (2, 4) with arecoline (5) and arecolone (6) or by isosteric substitution of the phenyl ring of DMPP, has been synthesized. Hybridization afforded compounds that, both as tertiary bases and as iodomethylates, have no affinity for the nicotinic receptor. On the contrary, isosteric substitution gave compounds that maintain affinity for the receptor; among them, two tertiary bases (37, 38), show affinity in the nanomolar range for the nicotinic receptor. The pharmacological profile of these isomeric compounds is quite interesting as they present differences in their peripheral and central effects, suggesting that they interact with different subtypes of the nicotinic receptor. Copyright (C) 1999 Elsevier Science Ltd.